Kyverna Therapeutics (KYTX)

• Market cap: $147M
• 1 day: 1.80%
• 5 days: -0.58%
• 1 month: -13.27%
• 3 months: -34.62%
• 6 months: -64.98%
• Year to date: -13.27%
• 1 year: -88.67%
• 5 years: -88.67%
• 10 years: -88.67%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 119

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

27% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 22

6% more funds holding

Funds holding: 88 [Q2] → 93 (+5) [Q3]

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

8.47% less ownership

Funds ownership: 79.14% [Q2] → 70.66% (-8.47%) [Q3]

41% less capital invested

Capital invested by funds: $256M [Q2] → $150M (-$106M) [Q3]

90% less call options, than puts

Call options by funds: $7K | Put options by funds: $67K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 76% upside
• Avg. target: $15 341% upside
• High target: $24 606% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 26% 1-year accuracy 43 / 165 met price target	76% upside $6	Neutral Maintained	20 Nov 2024
Wells Fargo Derek Archila 42% 1-year accuracy 15 / 36 met price target	606% upside $24	Overweight Maintained	15 Nov 2024